GSK to advance mRNA flu vaccine to late-stage trial

GSK

01/09/2026 07:11

Sept 1 (Reuters) - GSK GSK.L said on Tuesday it will advance its mRNA-based seasonal influenza vaccine candidate into a late-stage trial after mid-stage data showed it generated stronger immune responses than currently approved standard- and high-dose shots.

 (Reporting by Raechel Thankam Job in Bengaluru; Editing by Sherry Jacob-Phillips)
 ((RaechelThankam.Job@thomsonreuters.com;))